Device Trial Radar · NCT06275971
Effectiveness of Continuous Glucose Monitoring System Among Cardiac Surgery Patients
Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
68
Planned (sponsor's estimate)
Start
Nov 24, 2022
Primary completion
Jun 30, 2024
Study completion Aug 31, 2024
Sponsor
- Lead sponsor
- Kangbuk Samsung HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- DexCom, Inc.
- First posted
- Feb 23, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to assess the level of glycemic control and the incidence of surgery-related complications in cardiac patients post-surgery when Continuous Glucose Monitoring (CGM) is utilized, as compared to traditional methods of arterial/venous blood sampling and Point-of-Care Testing (POCT) for glucose monitoring.
Conditions
- Cardiac Disease
- PreDiabetes
- Diabetes Mellitus
Interventions
Dexcom G6Device
Glycemic control was monitored using CGM data for seven days following cardiac surgery
SMBG or venous/arterial blood glucoseDevice
Glycemic control was monitored using SMBG or venous/arterial blood glucose data for seven days following cardiac surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time within the target range of 100-180 mg/dLTime frame: 1-7 days after surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kangbuk Samsung Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.